Cervical Microbes Potentially Tied to Infections and Lesions
|
By LabMedica International staff writers Posted on 07 Mar 2019 |

Image: The Accuri C6 compact flow cytometer (Photo courtesy of BD Biosciences).
Nearly all cervical cancers are causally associated with human papillomavirus (HPV). The burden of HPV-associated dysplasias in sub-Saharan Africa is influenced by human immunodeficiency virus (HIV).
Changes in the cervicovaginal bacterial microbiome have been suggested to contribute to the development of precancerous cervical lesions. Chronic inflammation of the cervix (cervicitis), which is a result of cervicovaginal pathogens, leads to conditions like pelvic inflammatory disease (PID) and bacterial vaginosis (BV), both of which are associated with persistent HPV infection and cervical cancer.
An international team of scientists collaborating with the University of Nebraska (Lincoln, NE, USA) studied 144 women from Tanzania, who were 37 years old, on average. They noted that 41 of the women were HIV-positive, while 103 were negative for HIV. Just eight of the 134 women with available HPV test results were HPV-negative, and 126 were HPV-positive. All eight HPV-negative women were also negative for HIV.
Starting with 23 cervical cytobrush samples deemed free from intraepithelial lesions or malignancies, 72 samples from low-grade lesions and 50 samples from high-grade squamous lesions, the team amplified the 16S rRNA V4 hypervariable region and used deep Illumina sequencing to profile cervical microbe operational taxonomic units in relation to viral infection patterns and cervical cytology. Blood samples were collected via venipuncture into acid-citrate-dextrose tubes and processed using centrifugation at the on-site study laboratory within six hours of being drawn. The separated plasma was tested, using Standard Diagnostics HIV-1/2 3.0 detection kit and BD products CD4 FITC, CD8 PE, and CD3 Per CP antibodies to test the CD4 counts using a BD Accuri C6 Plus.
The team reported that at least half a dozen microbial phyla, including Firmicutes, turned up in the samples regardless of individuals' HIV or HPV infection status or cervical cytology. When they focused in on the microbes found in cervical communities from women with the risky, high-grade lesions, meanwhile, they saw a rise in Mycoplasmatales, Pseudomonadales, and Staphylococcus microbes in those cervical cancer-prone cases. From these and other data, the team proposed that chronic infection by microbes from the Mycoplasma genus such as M. genitalium and M. hominis may contribute to cervical dysplasia found in women positive for HPV. A further rise in Mycoplasma levels was found in samples from women with concurrent HIV infections, hinting that these microbes may offer insights into the microbiome features associated with risky cervical lesions. The study was published on February 19, 2019, in the journal mBio.
Related Links:
University of Nebraska
Changes in the cervicovaginal bacterial microbiome have been suggested to contribute to the development of precancerous cervical lesions. Chronic inflammation of the cervix (cervicitis), which is a result of cervicovaginal pathogens, leads to conditions like pelvic inflammatory disease (PID) and bacterial vaginosis (BV), both of which are associated with persistent HPV infection and cervical cancer.
An international team of scientists collaborating with the University of Nebraska (Lincoln, NE, USA) studied 144 women from Tanzania, who were 37 years old, on average. They noted that 41 of the women were HIV-positive, while 103 were negative for HIV. Just eight of the 134 women with available HPV test results were HPV-negative, and 126 were HPV-positive. All eight HPV-negative women were also negative for HIV.
Starting with 23 cervical cytobrush samples deemed free from intraepithelial lesions or malignancies, 72 samples from low-grade lesions and 50 samples from high-grade squamous lesions, the team amplified the 16S rRNA V4 hypervariable region and used deep Illumina sequencing to profile cervical microbe operational taxonomic units in relation to viral infection patterns and cervical cytology. Blood samples were collected via venipuncture into acid-citrate-dextrose tubes and processed using centrifugation at the on-site study laboratory within six hours of being drawn. The separated plasma was tested, using Standard Diagnostics HIV-1/2 3.0 detection kit and BD products CD4 FITC, CD8 PE, and CD3 Per CP antibodies to test the CD4 counts using a BD Accuri C6 Plus.
The team reported that at least half a dozen microbial phyla, including Firmicutes, turned up in the samples regardless of individuals' HIV or HPV infection status or cervical cytology. When they focused in on the microbes found in cervical communities from women with the risky, high-grade lesions, meanwhile, they saw a rise in Mycoplasmatales, Pseudomonadales, and Staphylococcus microbes in those cervical cancer-prone cases. From these and other data, the team proposed that chronic infection by microbes from the Mycoplasma genus such as M. genitalium and M. hominis may contribute to cervical dysplasia found in women positive for HPV. A further rise in Mycoplasma levels was found in samples from women with concurrent HIV infections, hinting that these microbes may offer insights into the microbiome features associated with risky cervical lesions. The study was published on February 19, 2019, in the journal mBio.
Related Links:
University of Nebraska
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







